xIPOmeter
Biocon Biologics
Динамика медиа-хайпа
- Неделя
- Месяц
- Год
- Медиа новости
- Новости эмитента
Данные на графике основываны на нашей проприетарной модели расчета ХP и могут подвергаться изменениям и уточнениям без предварительного уведомления
Оценка компании
- Оценка
- Цена за акцию
- Кумулятивный объем инвестиций
Данные в таблицах и графиках основаны на публичных источниках и несмотря на то что мы стараемся тщательно проверять эти данные, могут отличаться от реальных значений.
Новостной поток по компании Biocon Biologics125
Biocon BiologicsBiocon Biologics: Biocon Biologics inks licence pact with Janssen ...
The agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Biocon Biologics said ...
https://m.economictimes.com/industry/healthcare/biotech/biocon-biologics-inks-licence-pact-with-janssen-for-biosimilar-product/articleshow/108115136.cmsBiocon BiologicsBiocon Biologics Secures US Market Entry Date for Bmab 1200, a ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that ...
https://finance.yahoo.com/news/biocon-biologics-secures-us-market-145600619.htmlBiocon BiologicsBiocon Biologics Secures US Market Entry Date for Bmab 1200, a ...
Biocon Biologics and Janssen have finalized the settlement agreement to dismiss the pending Inter Partes Review (IPR) for US 10961307 before the Patent Trial ...
https://www.morningstar.com/news/pr-newswire/20240229ny49370/biocon-biologics-secures-us-market-entry-date-for-bmab-1200-a-proposed-biosimilar-to-stelaraBiocon BiologicsBiocon Biologics: Biocon Biologics focusing on market share gains ...
Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Europe....
https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-biologics-focusing-on-market-share-gains-of-biosimilars-in-key-markets/articleshow/107659099.cmsBiocon BiologicsBiocon Biologics: Focus on consolidation for the coming fiscal year
Shreehas Tambe of Biocon Biologics discusses the company's earnings results for the third quarter of fiscal year 2024 following its acquisition of ...
https://www.cnbc.com/video/2024/02/13/biocon-biologics-focus-on-consolidation-for-the-coming-fiscal-year.html
Показать ещё (120)Инвесторы4
Goldman Sachs
ADQTata CapitalTrue North